NCT06900218 2025-04-02
PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting
Clinical Trials
5 trialsNCT06485557 2024-07-03
A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC
Tang-Du Hospital
Phase 3 Not yet recruiting
NCT06089369 2024-04-30
Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion
Tongji Hospital
Phase 3 Not yet recruiting
NCT06089382 2023-10-18
A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection
Tongji Hospital
Phase 3 Not yet recruiting
NCT05244798 2022-10-25
Sintilimab Plus NCT or NCRT Versus NCRT for ESCC
Sichuan Cancer Hospital and Research Institute
Phase 3 Not yet recruiting